Triple Agonist Retatrutide Achieves 18.8% Weight Loss in Type 2 Diabetes Trial
Phase III TRIUMPH-2 trial shows retatrutide outperforms existing GLP-1 drugs in people with obesity and type 2 diabetes, slashing weight and HbA1c.
Summary
Retatrutide, an investigational drug targeting three hormone pathways — GLP-1, GIP, and glucagon — produced up to 18.8% body weight loss in adults with obesity and type 2 diabetes in a major phase III trial. Published in The Lancet and presented at the EASD annual meeting, the TRIUMPH-2 trial enrolled 1,152 participants over 80 weeks. The highest dose also reduced HbA1c by 1.45 percentage points and cut triglycerides by 35.6%, high-sensitivity C-reactive protein by 56.1%, and waist circumference by over 15 cm. These results surpass what semaglutide and tirzepatide have achieved in diabetic populations, suggesting that engaging all three hormone systems simultaneously may unlock greater metabolic benefit for people who historically lose less weight than those without diabetes.
Detailed Summary
Type 2 diabetes has long blunted the weight-loss response to even the best anti-obesity medications, leaving millions of people with obesity and diabetes underserved by existing therapies. Retatrutide, a novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, may be changing that picture in a meaningful way.
The phase III TRIUMPH-2 trial enrolled 1,152 adults with obesity and type 2 diabetes, randomizing them to retatrutide at 4 mg, 9 mg, or 12 mg doses, or placebo over 80 weeks. In the treatment regimen estimand, body weight fell by 11.9%, 16.8%, and 18.8% across the three doses, compared to 5.1% with placebo. The highest retatrutide dose translated to an average loss of 45.6 pounds. In the efficacy estimand — assuming full adherence — weight loss reached 20.8% at the 12-mg dose, a threshold previously unachieved in diabetic populations with pharmacotherapy.
Glycemic improvements were equally striking. Mean HbA1c reductions ranged from 1.38% to 1.50% versus 0.45% with placebo, and up to 40% of treated participants achieved normoglycemia, defined as HbA1c below 5.7%. Cardiometabolic markers also improved substantially: triglycerides fell by up to 35.6%, non-HDL cholesterol by 16.5%, high-sensitivity C-reactive protein by 56.1%, and waist circumference by 15.4 cm.
The mechanism driving these results is the simultaneous engagement of three appetite-regulating hormones acting centrally through both distinct and overlapping pathways. Lead investigator Dr. Juan Frias noted that in type 2 diabetes, recruiting all three systems appears necessary to overcome the metabolic resistance that blunts weight loss compared to non-diabetic individuals.
Caveats include a dropout rate of 3–11% due to adverse events, and results still fall short of the 28.3% weight loss seen in TRIUMPH-1, which tested the drug in people without diabetes. Retatrutide remains unapproved, and a gray market has already emerged. Long-term cardiovascular outcomes data are needed before clinical adoption.
Key Findings
- Retatrutide 12 mg produced 18.8% body weight loss (45.6 lb) over 80 weeks in adults with type 2 diabetes.
- Up to 40% of retatrutide-treated participants achieved normoglycemia with HbA1c below 5.7%.
- High-sensitivity C-reactive protein dropped by up to 56.1%, signaling broad cardiometabolic benefit.
- Triglycerides fell by 35.6% and waist circumference by 15.4 cm at the highest dose.
- Dropout rates of 3–11% due to adverse events indicate tolerability remains a meaningful concern.
Methodology
This is a meeting coverage news report summarizing a phase III randomized, double-blind, placebo-controlled trial (TRIUMPH-2) published simultaneously in The Lancet, a top-tier peer-reviewed journal. The trial enrolled 1,152 participants and ran for 80 weeks, providing strong evidence quality. The news article is written by a senior staff writer at MedPage Today, a credible medical journalism outlet.
Study Limitations
The article is a conference news report rather than a full methods paper, so details on randomization, baseline characteristics, and safety data are limited. The 3–11% dropout rate due to adverse events is reported without full characterization of event types or severity. Long-term cardiovascular outcomes, durability of weight loss post-discontinuation, and head-to-head comparisons with tirzepatide or semaglutide are not yet available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: